Ayurveda management in premature ovarian insufficiency- A case study

Premature ovarian insufficiency (POI) is defined as a cessation of ovarian function before the age of 40 years. It is associated with hypoestrogenism and loss of residual follicles, both of which lead to menstrual abnormalities, pregnancy failures, and decreased health-related quality of life. The prevalence of POI is estimated at 1% in the general population. The risk of premature ovarian insufficiency (POI) before the age of 40 years is 1 %. The aetiopathology of premature ovarian insufficiency in the majority of cases is unknown and is termed as spontaneous or idiopathic POI. This is a case with signs and symptoms of POI which was developed after the administration of GnRH agonist drugs as a part of treatment of endometriosis. In this single case study, a female of 33 years having complaints of absence of periods since 6 months treated with Ayurveda treatment with pre and post evaluation. The symptoms of secondary amenorrhoea, hot flashes, vaginal dryness and mood swings were relieved after Ayurveda medications and procedures.

Download Full-text

Neuropsychiatry service provision in India and South Asia

Oxford Textbook of Neuropsychiatry ◽

10.1093/med/9780198757139.003.0047 ◽

2020 ◽

pp. 545-550

Author(s):

Ennapadam S. Krishnamoorthy ◽

Vivek Misra

Keyword(s):

Quality Of Life ◽

South Asia ◽

Best Practice ◽

Medical Specialty ◽

Developing Nations ◽

Health Related Quality ◽

Related Quality ◽

Health Related

Neuropsychiatry as a medical specialty is significantly underrepresented in India, with neurology and psychiatry giving each other a wide berth in many of the country’s regions. This chapter reviews the state of neuropsychiatric services in India and South Asia, before moving on to explore what constitutes a Comprehensive Neuropsychiatry Programme (CNP). This encompasses education and research into neuropsychiatric outcomes, advocacy at a governmental level, and community-engendered activities, all with a view to attaining optimal levels of participation in activities of daily living (ADLs), health-related quality of life (HRQoL), and various social and educational milestones. The model employed by a multidisciplinary team for use in developing nations is then described, along with a case study to demonstrate best practice.

Download Full-text

The translation and validation of the Arabic Version of the Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (AR-PCOSQ)

BMC Women s Health ◽

10.1186/s12905-020-01108-0 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Sultan Alghadeer ◽

Alhanouf Algarawi ◽

Faten Abu-Rkybah ◽

Mashael M. Alshebly ◽

Yazed Alruthia

Keyword(s):

Quality Of Life ◽

Polycystic Ovarian Syndrome ◽

Signs And Symptoms ◽

Life Questionnaire ◽

Arabic Version ◽

Health Related Quality ◽

Related Quality ◽

Health Related ◽

Ovarian Syndrome

Abstract Background Polycystic ovarian syndrome (PCOS) is a hormonal disorder that is prevalent in females of reproductive age with signs and symptoms that significantly reduce self-esteem and have a negative impact on their quality of life. The management of PCOS signs and symptoms should result in an improvement in the health-related quality of life (HRQoL) of patients. Polycystic ovarian syndrome questionnaire (PCOSQ) is a disease-specific scale. The PCOSQ has been translated into different languages and assessed in different populations. The validity and reliability of PCOSQ varied depending on the ethnicity and culture of the respondents. The objective of the study was to establish a valid and reliable version of the PCOSQ (AR-PCOSQ) in Arabic. Methods A cross-sectional study using the translated and validated AR-PCOSQ questionnaire was conducted by interviewing 117 women with PCOS. Results The mean age (years) and BMI (kg/m2) of subjects were 29.90 ± 6.33 and 27.21 ± 5.54, respectively. Most of the patients had ≥ 1-year long history of PCOS (73.5%) and a post-school degree (64.96%). The content validity index (CVI) for the AR-PCOSQ from 10 gynecologists was 0.9, indicating satisfactory validity content. The internal consistency for reliability confirmation measured by Cronbach’s alpha coefficient was applied. Alpha coefficients for all items together was 0.863, indicating good reliability. The intraclass correlation coefficients for each item for 30 participants were also acceptable, ranging from 0.911 to 0.986 with p value < 0.001. As far as the factor analysis is concerned, the overall Kaiser–Meyer–Olkin sampling adequacy measure was 0.772. The Bartlett sphericity test was significant (p ≤ 0.001), Indicating that there were interrelated variables. Conclusion Our results demonstrated the initial reliability and validity of the Arabic version of the PCOSQ as a measure of specific HRQoL in Saudi women with PCOS. This will fill an important gap in measuring the HRQoL for patients with PCOS in research and community settings in Saudi Arabia. The AR-PCOSQ can be used to help prioritize health-related concerns from the patient’s perspective.

Download Full-text

Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study

Research in Social and Administrative Pharmacy ◽

10.1016/j.sapharm.2019.11.009 ◽

2020 ◽

Vol 16 (8) ◽

pp. 1095-1099

Author(s):

Hong Xiao ◽

Xinyi Jiang ◽

Cheng Chen ◽

Wei Wang ◽

Ching-Yu Wang ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Time Series ◽

Health Related Quality ◽

Menopausal Women ◽

Related Quality ◽

Health Related ◽

Post Menopausal

Download Full-text

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.16433 ◽

2020 ◽

Vol 34 (12) ◽

pp. 2809-2820 ◽

Cited By ~ 1

Author(s):

J.F. Merola ◽

K.A. Papp ◽

P. Nash ◽

J. Gratacós ◽

W.H. Boehncke ◽

...

Keyword(s):

Quality Of Life ◽

Psoriatic Arthritis ◽

Signs And Symptoms ◽

Health Related Quality ◽

Phase 3 ◽

Related Quality ◽

Health Related ◽

Skin Signs

Download Full-text

Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease

Acta Endocrinologica ◽

10.1530/eje-13-1013 ◽

2014 ◽

Vol 171 (1) ◽

pp. 89-98 ◽

Cited By ~ 14

Author(s):

Susan M Webb ◽

John E Ware ◽

Anna Forsythe ◽

Min Yang ◽

Xavier Badia ◽

...

Keyword(s):

Quality Of Life ◽

Cushing’S Disease ◽

Treatment Effectiveness ◽

Clinical Signs ◽

Signs And Symptoms ◽

Cushing's Disease ◽

Health Related Quality ◽

Related Quality ◽

Health Related

ObjectiveCushing's disease (CD) can significantly impair patients' health-related quality of life (HRQOL). This study investigated the treatment effectiveness of pasireotide on HRQOL of CD patients, and assessed the relationships between HRQOL and urinary free cortisol (UFC) and CD-related signs and symptoms.DesignIn this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily. The trial primary endpoint was UFC at or below ULN at month 6 without dose titration. Open-label treatment continued through month 12. HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.MethodsPearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed. Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6. Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.ResultsChange in CushingQoL was significantly correlated with changes in mUFC (r=−0.40), BMI (r=−0.39), weight (r=−0.41), and BDI-II (r=−0.54) at month 12 but not at month 6. The percentage of CushingQoL responders at month 12 based on month 6 mUFC control status were as follows: 63, 58.8, and 37.9% in the controlled, partially controlled, and uncontrolled groups respectively. Adjusted CushingQoL scores at month 12 were 58.3 for controlled patients (Δ=11.5 vs uncontrolled,P=0.012) and 54.5 for partially controlled patients (Δ=7.7 vs uncontrolled,P=0.170).ConclusionsPasireotide treatment can result in a meaningful HRQOL improvement among those who complete a 12-month treatment period, most often among patients achieving biochemical control.

Download Full-text